<DOC>
	<DOCNO>NCT01016795</DOCNO>
	<brief_summary>Clinical Hypothesis : It expect remove chemotherapy add ancestim mobilization scheme subject sufficient PBPC harvest minimum toxicity side effect .</brief_summary>
	<brief_title>Stem Cell Factor ( SCF ) Priming Haematopoietic Stem Cell Grafts Malignant Lymphoma</brief_title>
	<detailed_description>Autologous stem cell transplantation use support high dose chemotherapy haematological malignancies.1-2 Peripheral blood progenitor cell ( PBPC ) replace bone marrow cell prefer source transplantation due faster blood cell recovery.3-4 One variable major impact posttransplant care number PBPC harvested.5-8 Therefore , several clinical study aim identify prim regimen improve progenitor stem cell mobilization collection without increased toxicity . Frequently , Filgrastim ( r-met HuG-CSF ) administrate alone ; however , Filgrastim combine chemotherapy proven effective context CD34+ cell number harvested9-11 combination consider gold standard prim stem cell mobilization relapse malignant lymphoma . Stem cell factor ( SCF ) glycoprotein growth factor act haematopoietic blood cell progenitors.12 Whereas SCF alone exert little colony-stimulating activity normal human bone marrow cell vitro , combination SCF recombinant haematopoietic cytokine result synergistic increase number colonies.13 In vivo , addition SCF G-CSF ( Filgrastim ) synergistically increase PBPC mobilization compare Filgrastim alone.14-17 Several clinical trial report ability combination SCF Filgrastim mobilize PBPC patient lymphoma , multiple myeloma , breast ovarian cancer even heavily pretreated patients.18-26 Priming use chemotherapy toxic costly11 new priming procedure need establish , background randomize pilot study . The hypothesis elimination chemotherapy prim regimen may decrease overall toxicity ability collect sufficient autograft , however , may circumvent add r-metHuSCF ( Ancestim ) prim regimen . The aim randomize phase II trial evaluate safety , toxicity efficacy growth factor lymphoma patient consider candidate high dose chemotherapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Subjects Hodgkin 's disease nonHodgkin lymphoma ( Real classification ) relapse refractory initial chemotherapy partial response initial therapy Age &gt; 18 year &lt; 65 year ECOG performance status 0 , 1 2 Life expectancy &gt; 6 month treatment ANC &gt; equal 1.5 x 109/L , Platelets &gt; equal 100 x 109/L Serum creatinine &lt; equal 150 Âµmol/L , bilirubin , aspartate aminotransferase ( ASAT ) , alanine aminotransferase ( ALAT ) less twice upper limit define investigate laboratory Prior mobilization chemotherapy subject give write informed consent , personally dated Prior DexaBEAM miniBEAM therapy prior bone marrow PBPC transplant Any history seasonal recurrent asthma within precede 10 year . Any history anaphylactic / anaphylactoidtype event manifest disseminated urticaria , laryngeal oedema , / bronchospasm ( example , food , insect bite , etc. ) . Subjects drug allergy , manifest solely rash / urticaria , exclude Any history angioedema recurrent urticaria Clinical microbiological evidence infection date enrollment . Subjects concurrent malignancy Significant nonmalignant disease include document HIV infection , uncontrolled hypertension , unstable angina , congestive heart failure , poorly control diabetes , coronary angioplasty within six month , myocardial infarction within last six month , uncontrolled atrial ventricular cardiac arrhythmia Pregnant breast feeding subject childbearing potential use adequate contraceptive precaution Concurrent enrollment protocol use investigational drug Haematopoietic growth factor administer within one week study entry Subjects psychiatric , addictive disorder compromise ability give truly informed consent participation study Known sensitivity E. coli derive product Concurrent use beta adrenergic block agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>SCF</keyword>
	<keyword>Priming</keyword>
	<keyword>Mobilization</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Clinical Trial</keyword>
</DOC>